Verition Fund Management
PLRX icon

Verition Fund Management’s Pliant Therapeutics PLRX Stock Holding History

Verition Fund Management’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-262,698
Closed -$355K – 3805
2025
Q1 		$355K Buy
+262,698
New +$1.59M ﹤0.01% 2778
2024
Q3 		– Sell
-56,501
Closed -$607K – 3449
2024
Q2 		$607K Buy
+56,501
New +$728K ﹤0.01% 1948
2023
Q3 		– Sell
-17,700
Closed -$321K – 2607
2023
Q2 		$321K Sell
17,700
-23,102
-57% -$547K ﹤0.01% 1518
2023
Q1 		$1.09M Buy
+40,802
New +$1.16M 0.02% 912

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Verition Fund Management's PLRX Position: Q2 2025 in Review

Verition Fund Management sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 262,698 shares — an estimated $355K sold.

Verition Fund Management first reported a position in PLRX in Q1 2023 and held it in 4 quarters. The position peaked at $1.09M in Q1 2023. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • Verition Fund Management reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Verition Fund Management sold 262,698 Pliant Therapeutics shares in Q2 2025, an estimated $355K.
  • Verition Fund Management first reported a position in Pliant Therapeutics in Q1 2023 and held it in 4 quarters.
  • Verition Fund Management's Pliant Therapeutics position peaked at $1.09M in Q1 2023.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Verition Fund Management's 13F filing for Q2 2025, filed 14 Aug 2025.